A gel that softens on command: what if CRISPR’s scissor stroke were imitated?

A three-phase architecture (in silico → minimal → complete) with explicit GO/NO-GO/PIVOT criteria at each stage, constituting an exemplary strategy for risk management and resource optimisation.

The conceptual analogy with the CRISPR-Cas 'find-and-act' paradigm is intellectually stimulating and proposes a potentially significant departure from classical enzymatic 'lock-and-key' mechanisms (substrate cleavage).

The idea of using an aptamer as a mechanical transducer to modulate the stiffness of a hydrogel is conceptually elegant and aligns with a promising trend in bio-inspired materials.

The addressable market is clear and immediate: targeting MMP-9, a key biomarker in post-myocardial infarction matrix remodelling, cancer (metastasis) and inflammatory diseases, provides direct access to the smart therapeutic biomaterials market, estimated at $4.2 billion by 2028 (CAGR 14.5%). Initial potential customers are the R&D divisions of Medtronic, Boston Scientific and Johnson & Johnson, for stents or cardiac patches with programmed mechanical elution.

An original mechanism combining an aptamer, force transduction and a programmable hydrogel, with a clear and testable causal hypothesis.